The old and the new: Prospects for non-integrating lentiviral vector technology

Luis Apolonia*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)
102 Downloads (Pure)


Lentiviral vectors have been developed and used in multiple gene and cell therapy applications. One of their main advantages over other vectors is the ability to integrate the genetic material into the genome of the host. However, this can also be a disadvantage as it may lead to insertional mutagenesis. To address this, non-integrating lentiviral vectors (NILVs) were developed. To generate NILVs, it is possible to introduce mutations in the viral enzyme integrase and/or mutations on the viral DNA recognised by integrase (the attachment sites). NILVs are able to stably express transgenes from episomal DNA in non-dividing cells or transiently if the target cells divide. It has been shown that these vectors are able to transduce multiple cell types and tissues. These characteristics make NILVs ideal vectors to use in vaccination and immunotherapies, among other applications. They also open future prospects for NILVs as tools for the delivery of CRISPR/Cas9 components, a recent revolutionary technology now widely used for gene editing and repair.

Original languageEnglish
Article number1103
Issue number10
Early online date29 Sept 2020
Publication statusPublished - Oct 2020


  • CRISPR/Cas9
  • Immunotherapy
  • Insertional mutagenesis
  • Lentiviral vectors
  • Non-integrating lentiviral vectors (NILVs)
  • Transgene expression


Dive into the research topics of 'The old and the new: Prospects for non-integrating lentiviral vector technology'. Together they form a unique fingerprint.

Cite this